Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma

Annals of Hematology

Volumn 88, Issue 12, 2009, Pages 1229-1236

  Crocchiolo, Roberto ^a,b   Fallanca, F ^a   Giovacchini, G ^a   Ferreri, A J M ^a   Assanelli, A ^a   Verona, C ^a   Pescarollo, A ^a   Bregni, M ^c   Ponzoni, M ^a   Gianolli, L ^a   Fazio, F ^a   Ciceri, F ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c San Giuseppe Hospital   (Italy)

Author keywords

18FDG PET CT; Follow up; Hodgkin's lymphoma; Relapse

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; MITOXANTRONE; VINBLASTINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECURRENCE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 70350274590     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0752-4     Document Type: Article

References (35)

1. Zinzani PL, Tani M, Trisolini R et al (2007) Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 92:771-777. doi: 10.3324/haematol.10798
2. Isasi CR, Lu P, Blaufox MD (2005) A meta-analysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066-1074. doi: 10.1002/cncr.21253
3. Rigacci L, Vitolo U, Nassi L et al (2007) Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86:897-903. doi: 10.1007/s00277-007-0356-9
4. Schaefer NG, Strobel K, Taverna C et al (2007) Bone involvement in patients with lymphoma: The role of FDG-PET/CT. Eur J Nucl Med 34:60-67. doi: 10.1007/s00259-006-0238-8
5. Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N et al (2006) Positron emission tomography/computed tomography: Diagnostic accuracy in lymphoma. Br J Haematol 135:293-302. doi: 10.1111/ j.1365-2141.2006.06284.x
6. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752. doi: 10.1200/JCO.2007.11.6525
7. Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59. doi: 10.1182/blood-2005-06-2252
8. Haioun C, Itti E, Rahmouni E et al (2005) [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 106:1376-1381. doi: 10.1182/blood-2005-01-0272
9. Querellou S, Valette F, Bodet-Milin C et al (2006) FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 85:759-767. doi: 10.1007/s00277-006-0151-z
10. Schot BW, Zijlstra JM, Sluiter WJ et al (2007) Early FDG-PET assessment in combination with clinical risk scores determines prognosis in relapsed lymphoma. Blood 109:486-491. doi: 10.1182/blood-2005-11-006957
11. Spaepen K, Stroobants S, Dupont P et al (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419
12. Spaepen K, Stroobants S, Dupont P et al (2001) Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272-278. doi: 10.1046/j.1365-2141.2001.03169.x
13. Weihrauch MR, Re D, Scheidhauer K et al (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930-2934. doi: 10.1182/ blood.V98.10.2930
14. Juweid ME, Stroobants S, Hoekstra O et al (2007) Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 25:571-578. doi: 10.1200/JCO.2006.08.2305
15. Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989-3994. doi: 10.1182/ blood-2008-06-155820
16. Hutchings M, Loft A, Hansen M et al (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78:206-212. doi: 10.1111/j.1600-0609.2006.00802.x
17. Jerusalem G, Beguin Y, Fassotte MF et al (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14:123-130. doi: 10.1093/ annonc/mdg011
18. Schaefer HG, Taverna C, Strobel K et al (2007) Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy - is biopsy of FDG-avid lesions still needed? Radiology 244:257-262. doi: 10.1148/ radiol.2441060810
19. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586. doi: 10.1200/ JCO.2006.09.2403
20. Crocchiolo R, Canevari C, Assanelli A et al (2008) Pre-transplant FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 49:727-733. doi: 10.1080/10428190701885545
21. Cremerius U, Fabry U, Wildberger JE et al (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 30:103-111. doi: 10.1038/sj.bmt.1703607
22. Schot BW, Pruim J, van Imhoff GW et al (2006) The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 91:490-495
23. Filmont JE, Czernin J, Yap C et al (2003) Value of F-18-fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124:608-613. doi: 10.1378/ chest.124.2.608
24. Svoboda J, Andreadis C, Elstrom R et al (2006) Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 38:211-216. doi: 10.1038/ sj.bmt.1705416
25. Derenzini E, Musuraca G, Fanti S et al (2008) Pre-transplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 113:2496-2503. doi: 10.1002/cncr.23861
26. Dodero A, Crocchiolo R, Patriarca F et al (2007) Prognostic value of positron emission tomography (PET) scan in patients with relapsed Hodgkin lymphoma or aggressive non-Hodgkin lymphoma receiving salvage chemotherapy followed by reduced-intensity allogeneic stem cell transplantation. Blood Abs#3039
27. Torrey MJ, Poen JC, Hoppe RT (1997) Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies. J Clin Oncol 15:1123-1130
28. Radford JA, Eardley A, Woodman C et al (1997) Follow up policy after treatment for Hodgkin's disease: Too many clinic visits and routine tests? A review of hospital records. BMJ 314:343-346
29. Baron F, Storb R, Storer BE et al (2006) Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 24:4150-4157. doi: 10.1200/ JCO.2006.06.9914
30. Corradini P, Dodero A, Farina L et al (2007) Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 22:2316-2323. doi: 10.1038/sj.leu.2404822
31. Freytes CO, Loberiza FR, Rizzo JD et al (2004) Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry. Blood 104:3797-3803. doi: 10.1182/blood-2004-01-0231
32. Levine JM, Weiner M, Kelly KM (2006) Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 28:711-714. doi: 10.1097/ 01.mph.0000243648.66734.eb
33. Meany HJ, Gidvani VK, Minniti CP (2007) Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 48:399-402. doi: 10.1002/pbc.20797
34. Zinzani PL, Stefoni V, Tani M et al (2009) Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 27:1781-1787
35. Sonet A, Graux C, Nollevaux NC et al (2007) Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol 86:9-15. doi: 10.1007/s00277-006-0167-4